Ibrahim Halil Sahin1, Alexander I Geyer2, Daniel W Kelly2, Eileen Mary O'Reilly3. 1. Mount Sinai Icahn School of Medicine, St Luke's Roosevelt Hospital Center, New York, NY. 2. Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY. 3. Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY. Electronic address: oreillye@mskcc.org.
Abstract
BACKGROUND: Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer patients. PATIENTS AND METHODS: A total 2440 patients at Memorial Sloan Kettering Cancer Center were identified between January 1, 2000, and December 31, 2012, and were screened for grade 2 or higher GRP in an institutional tumor registry and using an ICD billing code database. Demographic and clinical information was extracted by electronic chart review. RESULTS: A total of 28 patients (1.1%) with GRP were identified. Incidence of grade 2, 3, and 4 reactions were 7 (25%), 18 (64%), and 3 (11%), respectively. No GRP-related mortality was observed. Twenty-one patients (75%) reported a history of cigarette smoking. Seventeen patients (61%) were alcohol users. Six patients (21%) were either regular or heavy drinkers. Most patients (93%) had either locally advanced or metastatic disease. Three patients (11%) underwent a diagnostic bronchoscopy, and in 1 patient a diagnosis of organizing pneumonia was established. Morbidity was significant; 3 patients (11%) required treatment in the intensive care unit. All hospitalized patients received steroid treatment. CONCLUSION: GRP is relatively uncommon but incurs significant morbidity. Potential risk factors include advanced-stage disease, along with smoking and alcohol consumption and possibly underlying lung disease. We recommend a high level of clinical alertness regarding the diagnosis, early pulmonary referral, and cessation of gemcitabine on suspicion of GRP.
BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancerpatients. PATIENTS AND METHODS: A total 2440 patients at Memorial Sloan Kettering Cancer Center were identified between January 1, 2000, and December 31, 2012, and were screened for grade 2 or higher GRP in an institutional tumor registry and using an ICD billing code database. Demographic and clinical information was extracted by electronic chart review. RESULTS: A total of 28 patients (1.1%) with GRP were identified. Incidence of grade 2, 3, and 4 reactions were 7 (25%), 18 (64%), and 3 (11%), respectively. No GRP-related mortality was observed. Twenty-one patients (75%) reported a history of cigarette smoking. Seventeen patients (61%) were alcohol users. Six patients (21%) were either regular or heavy drinkers. Most patients (93%) had either locally advanced or metastatic disease. Three patients (11%) underwent a diagnostic bronchoscopy, and in 1 patient a diagnosis of organizing pneumonia was established. Morbidity was significant; 3 patients (11%) required treatment in the intensive care unit. All hospitalized patients received steroid treatment. CONCLUSION: GRP is relatively uncommon but incurs significant morbidity. Potential risk factors include advanced-stage disease, along with smoking and alcohol consumption and possibly underlying lung disease. We recommend a high level of clinical alertness regarding the diagnosis, early pulmonary referral, and cessation of gemcitabine on suspicion of GRP.
Authors: Shannon M Lynch; Alina Vrieling; Jay H Lubin; Peter Kraft; Julie B Mendelsohn; Patricia Hartge; Federico Canzian; Emily Steplowski; Alan A Arslan; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; Sheila A Bingham; Paolo Boffetta; Marie-Christine Boutron-Ruault; Stephen J Chanock; Sandra Clipp; Robert N Hoover; Kevin Jacobs; Karen C Johnson; Charles Kooperberg; Juhua Luo; Catherine Messina; Domenico Palli; Alpa V Patel; Elio Riboli; Xiao-Ou Shu; Laudina Rodriguez Suarez; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Elissa Tong; Dimitrios Trichopoulos; Jarmo Virtamo; Weimin Ye; Kai Yu; Anne Zeleniuch-Jacquette; H Bas Bueno-de-Mesquita; Rachael Z Stolzenberg-Solomon Journal: Am J Epidemiol Date: 2009-06-26 Impact factor: 4.897
Authors: G Talamini; C Bassi; M Falconi; N Sartori; R Salvia; L Rigo; A Castagnini; V Di Francesco; L Frulloni; P Bovo; B Vaona; G Angelini; I Vantini; G Cavallini; P Pederzoli Journal: Dig Dis Sci Date: 1999-07 Impact factor: 3.199
Authors: H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno Journal: Thorax Date: 2003-10 Impact factor: 9.139
Authors: Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri Journal: J Clin Med Date: 2018-10-15 Impact factor: 4.241
Authors: Marcus Noel; Eileen M O'Reilly; Brian M Wolpin; David P Ryan; Andrea J Bullock; Carolyn D Britten; David C Linehan; Brian A Belt; Eric C Gamelin; Bishu Ganguly; Donghua Yin; Tenshang Joh; Ira A Jacobs; Carrie T Taylor; Maeve A Lowery Journal: Invest New Drugs Date: 2019-07-12 Impact factor: 3.850